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Until recently, the endothelium was regarded as a relatively
inert cell layer. However, over the past 20 years, research has
revealed an extraordinary array of endothelial functions, includ-
ing control over coagulation, fibrinolysis, arterial tone and vascu-
lar growth. Importantly, endothelial dysfunction has been impli-
cated as a key event in the pathogenesis of atherosclerosis,
coronary vasoconstriction and, probably, myocardial ischemia.
The recent demonstration that endothelial dysfunction may be
reversible raises the possibility of slowing the progression of
atherosclerosis or modifying arterial function, or both, to decrease
the risk of acute cardiovascular events.
(J Am Coll Cardiol 1997;30:325–33)
©1997 by the American College of Cardiology
For many decades the endothelium, the cell layer that lines the
blood vessels, was viewed simply as a semipermeable barrier
between blood and interstitium, facilitating the exchange of
water and small molecules. Recently, however, a series of
experiments have demonstrated that the endothelium has an
enormous range of vital homeostatic functions (1). Instead of
serving as an inert barrier, the endothelium is an antithrom-
bogenic vascular lining that also participates in metabolic,
synthetic and regulatory pathways (2).
Normal endothelial functions include control over throm-
bosis and thrombolysis, platelet and leucocyte interactions with
the vessel wall and regulation of vascular tone and growth (Fig.
1). Of particular interest to cardiologists, the endothelium
secretes both powerful vasorelaxing (e.g., nitric oxide [NO])
and vasoconstricting substances (e.g., endothelin-1 [ET-1])
(3,4).
Given that normal endothelial function plays a central role
in vascular homeostasis, it follows that endothelial dysfunction
probably contributes to disease states characterized by vaso-
spasm, vasoconstriction, excessive thrombosis or abnormal
vascular proliferation, alone or in combination, including
atherosclerosis and hypertension (Fig. 2).
Indeed in 1986, endothelial dysfunction was found in the
coronary arteries of humans with advanced atherosclerosis (5).
Subsequent work (6,7) has demonstrated that such endothelial
dysfunction predisposes to vasoconstriction at the site of
arterial plaque, instead of the more normal dilator response,
with potentially adverse clinical consequences. In 1992, endo-
thelial dysfunction was also demonstrated in asymptomatic
children and young adults with risk factors for atherosclerosis,
such as hypercholesterolemia and cigarette smoking (8).
Therefore, abnormal endothelial physiology has been impli-
cated both in early atherogenesis and later in the disease
process, in the control of dynamic plaque behavior. The
“biologic link” between endothelial damage and atherosclero-
sis may be related to decreased arterial bioavailability of NO,
which may predispose to leucocyte and platelet adhesion,
vasoconstriction and smooth muscle cell proliferation (9).
Normal Endothelial Function
The endothelium lies between the lumen and the vascular
smooth muscle. Although only one cell layer thick, it is able to
“sense” changes in hemodynamic forces, or blood-borne sig-
nals, by membrane receptor mechanisms and respond to
physical and chemical stimuli by synthesis or release of a
variety of vasoactive and thromboregulatory molecules and
growth factors. Substances released by the endothelium in-
clude prostacyclin, NO (the endothelium-derived relaxing fac-
tor [EDRF]), endothelins, endothelial cell growth factor(s),
interleukins, plasminogen inhibitors and von Willebrand factor
(Fig. 1). In addition to these “universal” functions, the endo-
thelium may have organ-specific roles that are differentiated
for various parts of the body, such as gas exchange in the lungs,
control of myocardial function in the heart or phagocytosis in
the liver and spleen.
Studies of endothelial structure and function have been
accomplished by a variety of techniques, including ultrastruc-
tural studies (10), in vitro experiments for endothelial cell
isolation and culture (11,12), physiologic studies in animals
(13) and, most recently, clinical studies in humans (5,8). This
knowledge has facilitated the development of certain treat-
ment strategies based on administration of endothelial prod-
ucts, such as prostacyclin and NO, or their antagonists.
Thromboresistance. The endothelium has anticoagulant,
antiplatelet and fibrinolytic properties. Endothelial cells are
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the major site for anticoagulant reactions involving thrombin
(14,15). Platelet adhesion to endothelial cells is markedly
inhibited by the endothelium-derived arachidonic acid metab-
olite prostacyclin (16,17). The same stimuli that activate plate-
lets, such as thrombin and adenosine diphosphate (ADP) and
adenosine triphosphate (ATP), also act to release prostacyclin
from the endothelium, which allows the endothelium to limit
the extent of platelet plug formation (18). The interactions
between platelets and endothelium regulate platelet function,
coagulation cascades and local vascular tone (19).
In addition, endothelial cells may secrete tissue-type plas-
minogen activator (t-PA) (20), the powerful thrombolytic
agent in frequent clinical use for treatment of coronary throm-
botic occlusion. t-PA release is stimulated in vivo by norepi-
nephrine, vasopressin or stasis within the vessel lumen. Throm-
bin may also stimulate t-PA release, providing a further
endothelium-mediated safeguard against uncontrolled coagu-
lation.
Regulation of vascular tone. The central role of the endo-
thelium in controlling vascular tone has only been appreciated
since the discovery of the potent vasodilators prostacyclin and
NO (16,21). The endothelium controls underlying smooth
muscle tone in response to certain pharmacologic and physio-
logic stimuli (22). This involves a number of lumen membrane
receptors and complex intracellular pathways and the synthesis
and release of a variety of relaxing and constricting substances,
described below. In addition to making their own vasoactive
mediators, endothelial cells may transduce signals from, or
even inactivate, circulating vasodilators and constrictors, such
as thrombin, bradykinin, ADP and ATP (23).
NO, an EDRF. The existence of an endothelial relaxing
factor was first postulated by Furchgott and Zawadzki (21) in
1980, when they noticed that rabbit aortic rings relaxed in
response to acetylcholine only in the presence of an intact
endothelium. The biologic effects of EDRF are mediated by
NO. NO is synthesized from L-arginine by an enzyme, nitric
oxide synthase (NOS) (24). The reaction is stereospecific, and
L-arginine is converted to NO and L-citrulline. The generation
of NO from L-arginine can also be specifically blocked by
arginine analogues, such as NG-monomethyl-L-arginine (L-
NMMA), which has recently proved to be a useful tool in
clinical research, allowing investigation of the biologic distri-
Abbreviations and Acronyms
ACE 5 angiotensin-converting enzyme
ADP 5 adenosine diphosphate
ATP 5 adenosine triphosphate
EDRF 5 endothelium-derived relaxing factor
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NO 5 nitric oxide
NOS 5 nitric oxide synthase
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Figure 1. Some functions of normal endothelium. Fac-
tors secreted into the lumen (upward arrows) include
prostacyclin and t-PA, which influence coagulation. Cell
surface adhesion molecules (such as intercellular adhe-
sion molecule-1 [ICAM-1] and vascular cell adhesion
molecule-1 [VCAM-1]) regulate leucocyte adhesion.
Factors secreted abluminally (toward the smooth muscle
[downward arrows]) may powerfully influence vessel
tone and growth. Coronary artery and endocardial en-
dothelium may also influence myocardial contractility
(41).
Figure 2. Some consequences of endothelial dysfunction. In the
presence of certain risk factors, endothelial cells may produce less NO
or more oxygen-derived free radicals (such as O2
2), or both. These
changes may in turn result in certain proischemic or proatherogenic
effects, as indicated, including increased transcription of certain redox-
sensitive proinflammatory genes (Marui N, Offermann MK, Swerlick
R, et al. Vascular cell adhesion molecule-1 (VCAM-1) gene transcrip-
tion and expression are regulated through an antioxidant-sensitive
mechanism in human vascular endothelial cells. J Clin Invest 1993;92:
1886–94). Agents that can lead to increased NO bioavailability in the
vessel wall, or decreased O2
2 production, may be useful in reversing
endothelial dysfunction (see text). In addition, decreased endothelial
production of the anticoagulant vasodilator prostacyclin or increased
production of the vasoconstrictor ET-1 may also be pathogenetically
important consequences of endothelial dysfunction.
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bution and role of NO. NOS has at least three isoforms,
including constitutively expressed and inducible enzymes.
NO maintains low arterial tone at rest, in both the systemic
and pulmonary circulations (25–27). In addition, NO release is
stimulated by increased flow (leading to increased shear stress
on the endothelium) (28) and by bradykinin, thrombin, acetyl-
choline and a variety of other circulating agents that increase
EDRF release through activation of specific endothelial cell
membrane receptors (22).
The vasodilator activity of NO is due to interaction with the
iron atom of heme in guanylate cyclase, causing its activation
and thereby increasing intracellular cyclic guanosine mono-
phosphate levels (29,30). In smooth muscle cells, this results in
a reduction of intracellular calcium and thereby relaxation
(31). The same pathway is involved in the mechanism of action
of exogenous nitrovasodilators, such as sodium nitroprusside
and nitroglycerin.
Endothelium-derived hyperpolarizing factor. Stimulation
of the normal endothelium by acetylcholine also produces
hyperpolarization of the underlying smooth muscle and
thereby vasorelaxation. This is not mediated by NO, but by
another endothelium-derived factor, which acts by increasing
K1 conductance. The resulting vasodilation is not inhibited by
L-NMMA, the specific antagonist of NO (32,33). In contrast
ouabain, a Na1/K1-ATPase inhibitor, does not affect NO-
induced relaxation, but prevents the action of endothelium-
derived hyperpolarizing factor. The precise identity and phys-
iologic role of this factor are uncertain.
Prostacyclin. Another major endothelium-derived vasodi-
lator is prostacyclin, which is produced from arachidonic acid
through the enzyme cyclooxygenase (16). Prostacyclin also has
antithrombotic and antiplatelet activity. Its release may be
stimulated by bradykinin and adenine nucleotides. Like NO, it
is chemically unstable, with a short half-life (34). However,
unlike NO, prostacyclin acts through stimulation of adenylate
cyclase and an increase in intracellular levels of cyclic AMP. It
is a potent vasodilator and is active in both the pulmonary and
systemic circulations.
Endothelins (endothelium-derived contracting factors).
Endothelin is an extremely potent vasoconstrictor that was
isolated, purified and sequenced in 1988 (4). This 21-amino
acid peptide is closely related to the snake venom sarafatoxin
and is one of the most potent vasoconstrictors yet identified.
There are three isoforms of endothelin, but only one (ET-1)
has been shown (35) to be released from human endothelial
cells. Like NO, ET-1 is synthesized in the endothelial cells and
released in response to a variety of stimuli, such as adrenaline
and hypoxia (36). ET-1 has a short half-life (37), suggesting
that it, too, is mainly a locally active vasoregulator. Its physi-
ologic role includes maintenance of basal vascular resistance,
and it is present in healthy subjects in low concentrations (38).
Elevated endothelin levels have been found in systemic and
pulmonary hypertension, coronary artery disease and heart
failure; in these conditions, a pathologic role has been postu-
lated but not proved (39,40).
In addition, normal endothelium also plays an important
role in vascular growth, monocyte adhesion, immunologic
regulation, metabolism of circulating amines, lipoprotein me-
tabolism and integration and transduction of blood-borne
signals. Endocardial and coronary microvascular endothelium
may also regulate myocardial contractility (41).
Clinical Assessment of Endothelial Function
Over the past decade, a large number of studies have
assessed arterial endothelial function in health and disease.
Most of these have tested the ability of normal endothelium to
release the vasorelaxing factor NO in response to pharmaco-
logic or physiologic stimuli, or both. Although this is only one
of many endothelial functions, NO release may be particularly
important because of its actions on platelets, monocytes and
smooth muscle cells (9).
Coronary artery testing. In vivo assessment of coronary
endothelial function in humans was first reported in the
mid-1980s (5) (Fig. 3). Coronary artery diameter was measured
by quantitative angiography before and after intracoronary
Figure 3. In 1986, Ludmer et al. (5) showed
paradoxic coronary vasoconstriction at plaque
sites, suggesting endothelial dysfunction (*p ,
0.001). These data first suggested an important
role for endothelial physiology in determining
dynamic plaque behavior at the sites of coronary
artery stenosis. ACh 5 acetylcholine; TNG 5
trinitroglycerin. Adapted, with permission, from
Ludmer et al. (5). Copyright 1986, Massachu-
setts Medical Society. All rights reserved.
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infusion of acetylcholine. In normal arteries, acetylcholine
stimulated the endothelial release of NO, resulting in vasodi-
lation, whereas in subjects with endothelial dysfunction, vaso-
constriction was observed (due to a direct smooth muscle
constrictor effect of acetylcholine). This response was con-
trasted with the response to nitroglycerin, an exogenous source
of NO and therefore an endothelium-independent vasodilator.
Soon after, invasive testing of coronary microvascular endo-
thelium was described (42) by measuring the response of
coronary flow to administration of endothelium-dependent
and -independent small-vessel dilator substances, using Dopp-
ler wires or catheters.
These techniques have given valuable insights into the risk
factors for coronary endothelial dysfunction in angiographi-
cally smooth arteries (43,44) and into the role of endothelial
dysfunction in predisposing to dynamic plaque activation and
constriction (5,6,45). More recently, the potential for revers-
ibility of endothelial dysfunction in the coronary arteries has
been assessed using this methodology to assess novel thera-
peutic strategies (e.g., cholesterol-lowering therapy and
angiotensin-converting enzyme [ACE] inhibition) (46–48)
(see later).
Peripheral artery testing. The major disadvantage of intra-
coronary testing is its invasive nature, and it is therefore
generally unsuitable for use in children or adults who are at
high risk of atherosclerosis but who have no clinical symptoms
or signs of disease. For this reason, noninvasive or minimally
invasive clinical tests of endothelial function have been devel-
oped. Noninvasive detection of endothelial dysfunction in the
brachial and femoral arteries was first described in 1992 (8)
(Fig. 4). In this test, arterial diameter is measured in response
to an increase in shear stress, which causes endothelium-
dependent dilation, and in response to sublingual nitroglyc-
erin, an endothelium-independent dilator.
The brachial artery dilator response to shear stress has been
shown to be reproducible (49), due mainly to endothelial
release of NO (50), and to correlate well with invasive testing
of coronary endothelial function (51). Endothelial function has
also been extensively investigated in the forearm microcircu-
lation by intraarterial infusion of endothelium-dependent and
-independent vasodilator substances, followed by measure-
ment of forearm flow using plethysmographic techniques
(52,53). Although these peripheral artery techniques provide
only “surrogate” measures of coronary endothelial function,
they have provided important insights into the risk factors for
atherogenesis in childhood and young adult life and are also
being used in studies of reversibility of endothelial dysfunction
in asymptomatic subjects at high risk of arterial disease (54,55).
Endothelial Dysfunction in
Early Atherogenesis
Endothelial injury, either physical trauma or more subtle
cellular damage, is now regarded as an important initial event
in atherogenesis (56,57). Even in nomocholesterolemic ani-
mals, physical damage to the endothelium can lead to athero-
sclerotic lesion formation (58). Hypertension has been shown
experimentally to disrupt endothelial integrity (59). Hyperho-
mocysteinemia, which causes chemical endothelial injury, is
associated with premature atherosclerosis and thrombosis
(60). The finding that many of these insults, which are associ-
ated with clinical progression of vascular disease, are clearly
related to endothelial injury has added weight to the “response
to injury” hypothesis of Ross and Glomset (61) and its later
modifications (56). Other hypotheses have also been proposed
to explain the initiating events in atherosclerosis (62).
The consequences of endothelial damage that promote
fatty streak and plaque formation include increased adherence
of monocytes (63), increased permeability to monocyte/
macrophages and lipoproteins, which then accumulate in the
vessel wall, increased platelet adherence and increased smooth
muscle cell migration and proliferation (64). The latter may be
mediated by loss of endothelium-derived heparin-like oligosac-
charides, which normally inhibit smooth muscle cells (65), or
by allowing platelet adhesion and thereby increased local
concentration of platelet derived growth factor, which is also
an important smooth muscle mitogen (66). Endothelial dys-
function may also be accompanied by decreased local avail-
ability of NO. This may be due to decreased endothelial
production of NO or to excess production of superoxide
anions, or both, with consequent degradation of NO before it
can reach its target tissues. For example, superoxide produc-
tion is enhanced in the presence of hypercholesterolemia, with
consequently decreased bioavailability of NO (67). Because
NO is a local vasodilator and also inhibits platelet adherence
and aggregation, smooth muscle proliferation and endothelial-
cell leucocyte interactions, reduced NO activity may also
contribute to the initiation and progression of atherogenesis
(9). Indeed, supplementation with oral L-arginine, the physio-
logic substrate for NO production, has profound antiathero-
Figure 4. Endothelial dysfunction is also important in the early stages
of atherogenesis; for example, significantly impaired endothelium-
dependent flow-mediated dilation (EDD) has been found in asymp-
tomatic children and young adults with risk factors for atherosclerosis,
such as hypercholesterolemia and cigarette smoking. Adapted, with
permission, from Celermajer et al. (8).
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genic effects in cholesterol-fed animals (68) and has recently
been associated with decreased platelet aggregation (69) and
monocyte/endothelial cell adhesion (70) in humans.
Endothelial dysfunction has been demonstrated in asymp-
tomatic children and young adults with risk factors for athero-
sclerosis (8). Hypercholesterolemia is associated with arterial
endothelial dysfunction in children as young as 7 years old,
with significant correlations between the degree of endothelial
impairment and the levels of both low density lipoprotein
(LDL) cholesterol and lipoprotein(a) (71). Both active ciga-
rette smoking (72) and even prolonged exposure to environ-
mental tobacco smoke (73) have been shown to be associated
with impaired endothelium-dependent dilation, in a dose-
dependent manner, in otherwise healthy teenagers and young
adults. Aging, too, has been associated with progressive endo-
thelial impairment (74,75), and this age-related dysfunction
appears to occur earlier in men than in women (76). Endothe-
lial dysfunction has also been implicated in the pathogenesis of
hypertension. Many studies have found impaired endothelial
release of NO in hypertensive subjects (77–79), although one
large study has failed to confirm this finding (80). Overproduc-
tion of ET-1 may also produce hypertension (81). However, it
is unclear whether abnormal endothelial production of vaso-
active factors can be a primary cause of high blood pressure
rather than simply an effect of the hypertensive state.
It has also been shown (44,82) that the traditional vascular
risk factors may interact to damage the endothelium in asymp-
tomatic subjects, in the same way as they are known to interact
in determining the risk of clinical cardiovascular end points. In
the coronary circulation, endothelial dysfunction is not only
observed at the sites of obstructive stenoses, but has also been
documented in angiographically smooth arteries of subjects
with risk factors for atherosclerosis (43,44). Taken together,
these data from in vivo human studies indicate the importance
of impaired endothelium-dependent NO-mediated dilation in
the early stages of the atherosclerotic process.
Some limitations apply to these studies. To date, large-
vessel endothelial function has only been investigated in
asymptomatic children and young adults using peripheral
arteries (such as the brachial and femoral), which can be
studied noninvasively. Invasive coronary studies are confined
to symptomatic patients and therefore may suffer from a
selection bias. Nevertheless, there appears to be good corre-
lation between coronary and peripheral artery endothelial
function in the same subjects (51). Furthermore, no longitudi-
nal studies in humans have yet proved that those young
subjects with endothelial dysfunction will go on to develop
advanced atherosclerosis; such studies would take decades to
complete. Despite this limitation, endothelial dysfunction is
spatially and temporally linked to atherosclerosis; endothelial
dysfunction occurs first at coronary branch points (83), as do
advanced plaques; and endothelial dysfunction also precedes
occlusive arterial disease in both the experimental primate
model (84) and in human heart transplant recipients (85).
These data serve to support an important link between arterial
endothelial impairment and later advanced atherosclerotic
disease.
Endothelial Dysfunction in
Advanced Atherosclerosis
Obstructive coronary stenoses are usually thought to con-
tribute to angina pectoris by providing a fixed limitation to
coronary flow during periods of increased myocardial oxygen
demand (e.g., during exertion). However, a series of studies
over the past 10 years (5,6,45,86) has shown that coronary
stenoses are dynamic rather than fixed and that impaired
endothelium-dependent dilation at the site of coronary
plaques may result in paradoxic vasoconstriction during exer-
cise or mental stress, just when coronary vasodilation is most
required.
In 1986, Ludmer et al. (5) first demonstrated this phenom-
enon in human coronary arteries. Whereas normal arteries
dilated in response to intracoronary acetylcholine, which stim-
ulates endothelial NO production, stenotic arteries showed
paradoxic vasoconstriction. Subsequent studies demonstrated
that coronary endothelial dysfunction (assessed as an abnor-
mal response to acetylcholine) also resulted in impaired flow
mediated coronary dilation in response to intracoronary pa-
paverine (45), cardiac pacing (87) and physiologic levels of
exercise (6). Abnormal coronary responses to serotonin in the
presence of endothelial dysfunction may be particularly impor-
tant in unstable coronary syndromes in vivo, given the involve-
ment of (serotonin containing) platelets in the pathophysiology
of these processes (88).
Similar endothelial dysfunction also occurs in the coronary
microcirculation, particularly in response to hypercholesterol-
emia (89). Because endothelial vasodilator function of the
coronary microvessels may be an important determinant of
myocardial perfusion during periods of increased demand,
microvascular endothelial dysfunction may play a particularly
significant role in the pathogenesis of myocardial ischemia
(90,91).
Some studies have demonstrated heterogeneous endothe-
lial responses within the same coronary artery or within the
same patient (92), and this finding is consistent with in vitro
experiments demonstrating nonuniform endothelial cell be-
havior when exposed to apparently similar conditions of shear
stress (93). However, most studies overall have consistently
reported the presence of impaired endothelium-dependent
dilation in atherosclerotic coronary vessels. Although serial
coronary physiologic studies are only infrequently performed,
recent intervention trials (46–48) have reported coronary
endothelial responses before and after 6 months of placebo
treatment; in these studies, the endothelial responses to ace-
tylcholine appeared highly reproducible.
The clinical correlate of impaired endothelial function in
the coronary arteries may be episodic myocardial ischemia,
either with or without chest pain. It has recently been ob-
served, for example, that cholesterol-lowering therapy may
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result in significantly decreased myocardial ischemia (94,95)
and improved cardiovascular survival in patients with coronary
atherosclerosis (96,97). These benefits have occurred even
though angiographic regression trials of cholesterol lowering
have demonstrated only very minor (if any) regression of
actual coronary plaque size (98,99). The mechanism for clinical
improvement in the absence of coronary anatomic changes
might relate to beneficial endothelial effects; that is, coronary
function rather than structure might improve, resulting in
fewer clinical symptoms and events. Alternate hypotheses for
this observation include plaque remodeling or stabilization, or
both, and a decreased tendency to thrombosis as the mecha-
nisms for clinical benefit.
Coronary endothelial injury may also play an important role
in postangioplasty restenosis (100). Balloon angioplasty always
results in some degree of endothelial injury, and the response
to this injury includes growth factor secretion and consequent
myointimal proliferation. Again, the role of endothelium-
derived NO may be particularly important, with the recent
demonstration in experimental studies (101) that local trans-
fection of endothelial cells with NO synthase after angioplasty
may attenuate this proliferative response, with a consequent
decrease in the incidence of restenosis.
Reversibility of Endothelial Dysfunction
Current research is examining strategies that might improve
arterial endothelial function. This is an attractive possibility; if
such strategies could be implemented early in the disease
process, it might be possible to prevent or retard atherogene-
sis. Even in advanced disease, modification of coronary artery
endothelial dysfunction might decrease the propensity to va-
soconstriction or thrombosis, or both, and thereby decrease the
risk of acute cardiovascular events.
Coronary endothelial function can be improved in hyper-
cholesterolemic subjects by lipid lowering (46,47), either short
term, for example, by LDL apheresis (102), or in the longer
term, with either diet and resin therapy (103) or HMG CoA
reductase inhibitors such as lovastatin. In these latter studies,
coronary vasoconstriction observed at baseline was signifi-
cantly attenuated after cholesterol-lowering treatment for 6
months. Improved dilation has been particularly observed in
patients treated with a combination of cholesterol-lowering
and antioxidant therapy (46), highlighting the importance of
oxidative stress in the pathogenesis of endothelial dysfunction.
Oral administration of high dose vitamin C has also been
shown (55) to improve brachial artery endothelial function in
patients with established coronary disease, although it is not
known whether this effect is sustained with prolonged therapy.
Improvement in endothelial function has also been ob-
tained by therapeutic manipulation of the L-arginine–NO
pathway. Short-term parenteral administration of L-arginine
has been associated with improved coronary and peripheral
microvascular function (89,104), and a recent study (54) has
demonstrated improved endothelium-dependent dilation in
young hypercholesterolemic subjects given oral L-arginine for 4
weeks (Fig. 5). However, animal data suggest that the benefi-
cial effects of L-arginine on endothelial function and athero-
sclerosis may not be sustained over the long term (105),
although the experimental data on this point are not consistent
(106).
ACE inhibition with quinapril has also been shown (48) to
improve coronary endothelial function in patients with athero-
sclerosis. This effect may contribute to the potential anti-
ischemic effect of this class of drugs and may be mediated in
part by suppression of vascular wall superoxide production and
consequently by enhanced bioavailability of NO (107). Such
findings suggest important links between the renin–angiotensin
and the L-arginine–NO systems in the vessel wall. Some animal
data have indicated that calcium channel blocking agents, as
well as angiotensin blockade, might improve endothelial dys-
function in experimental models of hypertension (108), and
short-term calcium channel antagonism has recently been
associated with improved coronary vasomotion in hypertensive
humans (109); however, long-term human studies with calcium
channel blockers have not yet been reported.
Estrogen therapy has also been shown (100–112) to have a
beneficial effect on endothelial function in postmenopausal
women. This effect may mediate some of the apparent cardio-
protective benefit of estrogen replacement in older women.
Recent data (113,114) indicate that the addition of progester-
one to estrogen, in combined hormone replacement therapy,
may also be associated with beneficial effects on endothelial
function.
Early data suggest that the same therapeutic strategies that
improve arterial endothelial function may also be associated
with a decrease in myocardial ischemia and with ischemic
events rates. For example, cholesterol-lowering therapy not
only improves coronary endothelial physiology in hypercholes-
terolemic subjects, but may also significantly reduce the num-
ber and duration of transient myocardial ischemic episodes
Figure 5. Endothelial dysfunction may be reversible under certain
circumstances. In this example (54), impaired endothelium-dependent
dilation (EDD) in young adults with hypercholesterolemia was im-
proved significantly by 4 weeks of treatment with L-arginine, the
precursor of NO. Reprinted, with permission of the American Society
for Clinical Investigation, from Clarkson et al. (54).
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(94,95). Furthermore, ACE inhibition may improve coronary
endothelial physiology and may also reduce the incidence of
clinical cardiovascular events (115). Although there may be
other non–endothelium-related benefits of these therapeutic
manipulations, it is possible that at least some of the observed
benefit of such interventions may relate to reversibility of
endothelial dysfunction.
Future Directions
Diagnosis. A simple noninvasive test for endothelial dys-
function would potentially have immediate clinical applicabil-
ity. Such a test might identify presymptomatic subjects at high
risk of atherosclerotic complications and therefore allow spe-
cific “targeting” of primary preventive strategies. Although
endothelial function testing is available in the research setting,
no technique yet exists that is simple, safe, reproducible and
easily performed as a screening method.
Treatment. Current research has raised the exciting possi-
bility that endothelial dysfunction might be reversible with
certain interventional strategies (46–48,54,55). In the case of
naturally occurring substances, such as L-arginine and vitamin
C, future studies in humans will be directed toward defining
the sustainability of any beneficial arterial effects with pro-
longed therapy. Certain pharmacologic agents have been iden-
tified that result in improved endothelial function over at least
a 6-month period (46–48). It is now important to investigate
whether such improvements in arterial physiology will be
correlated with evidence of clinical benefit.
Potentially, the most exciting future direction relates to
improvement of arterial endothelial function in children and
young adults, early in the atherogenic process. Intuitively, it is
at this early stage that arterial wall damage is most likely to be
easily reversible (116). If strategies to protect the endothelium
early in life can be defined and applied successfully, this may
have important public health benefits into the next millenium.
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